WT1基因 rs16754位点多态性与急性髓系白血病预后关系的 Meta 分析

Relationship between WT1 gene polymorphism rs16754 and prognosis of acute myeloid leukemia：a meta-analysis

目的：采用 Meta 分析总结 WT1基因 rs16754位点多态性与急性髓系白血病（AML）预后的关系。方法以英文检索词“WT1”“polymorphism”“Leukemia，Myeloid，Acute”检索 PubMed 数据库，同时以中文检索词“WT1”“多态性”“急性髓系白血病”检索中国知网、万方数据库和中国生物医学文摘数据库，时限截至2015年12月1日。结果共纳入11篇英文文献，样本量共计2789例。 Meta 分析结果显示， WT1基因 rs16754位点多态性与 AML 患者化疗完全缓解情况无相关性（RR＝1.02，95% CI 0.99～1.06， P＝0.20），与总体生存（OS）（HR＝0.68，95% CI 0.45～1.02，P＝0.06）、5年 OS（RR＝1.10，95% CI 0.90～1.34，P＝0.37）及无复发生存期（RFS）（HR＝0.80，95% CI 0.54～1.19，P＝0.27）也无相关性。结论 WT1基因 rs16754位点多态性与 AML 预后各指标无相关性。

Objective To analyze the relationship between WT1 gene polymorphism rs16754 and prognosis of acute myeloid leukemia （AML） by meta-analysis. Methods Studies published in PubMed, CNKI, WanFang and CBM database were searched by using the search terms ＇WT1＇, ＇Polymorphism＇ and ＇Leukemia, Myeloid, Acute＇, respectively. Deadline was December 1, 2015. Results A total of 11 English articles with a total of 2 789 patients were included. Meta-analysis showed that there was no association between polymorphism rs16754 and complete remission of AML patients （RR=1.02, 95 % CI： 0.99~1.06, P=0.20）, overall survival（OS） （HR=0.68, 95 % CI： 0.45~1.02, P=0.06）, 5-year OS （RR=1.10, 95 % CI：0.90~1.34, P=0.37） or relapse-free survival （RFS） （HR=0.80, 95 % CI： 0.54~1.19, P=0.27）. Conclusion There is no correlation between WT1 gene polymorphism rs16754 and the prognosis of AML.